NKTX
Nkarta, Inc. NASDAQ Listed Jul 10, 2020$3.15
Pre-mkt
$3.20
+1.59%
Mkt Cap $224.6M
52w Low $1.63
75.2% of range
52w High $3.65
50d MA $2.54
200d MA $2.19
P/E (TTM)
-2.1x
EV/EBITDA
-1.6x
P/B
0.7x
Debt/Equity
0.2x
ROE
-33.3%
P/FCF
-1.5x
RSI (14)
—
ATR (14)
—
Beta
0.67
50d MA
$2.54
200d MA
$2.19
Avg Volume
785.9K
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
6000 Shoreline Court · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.32 | -0.37 | -15.6% | 2.13 | +0.0% | +0.5% | -3.3% | -6.1% | -0.9% | +2.8% | — |
| Nov 10, 2025 | AMC | -0.32 | -0.29 | +9.4% | 1.96 | +0.0% | +2.6% | +0.0% | -4.1% | -4.6% | -7.7% | — |
| Aug 12, 2025 | AMC | -0.37 | -0.31 | +16.2% | 1.96 | +2.0% | +12.8% | +12.2% | +18.9% | +19.9% | +17.3% | — |
| May 14, 2025 | AMC | -0.44 | -0.43 | +2.3% | 1.87 | -4.8% | -8.0% | -7.0% | -9.1% | -3.7% | -9.1% | — |
| Mar 26, 2025 | AMC | -0.41 | -0.35 | +14.6% | 1.37 | +11.7% | +43.8% | +46.0% | +34.3% | +35.0% | +39.4% | — |
| Nov 7, 2024 | AMC | -0.37 | -0.39 | -5.4% | 3.27 | +0.6% | -2.4% | +3.7% | -6.7% | -11.0% | -17.4% | — |
| Aug 13, 2024 | AMC | -0.49 | -0.34 | +30.6% | 4.97 | +9.7% | +3.2% | +0.8% | +2.0% | +4.8% | +2.8% | — |
| May 9, 2024 | AMC | -0.56 | -0.58 | -3.6% | 6.30 | +3.2% | -0.8% | +4.4% | +4.0% | +9.2% | +8.3% | — |
| Mar 21, 2024 | AMC | -0.62 | -0.57 | +8.1% | 12.98 | -23.0% | -31.3% | -19.2% | -24.0% | -14.6% | -16.7% | — |
| Nov 9, 2023 | AMC | -0.67 | -0.52 | +22.4% | 2.05 | +6.3% | -1.0% | -6.8% | +12.2% | +21.0% | +14.9% | — |
| Aug 10, 2023 | AMC | -0.69 | -0.68 | +1.4% | 2.03 | +0.0% | -2.0% | -2.0% | -2.5% | -3.4% | -6.9% | — |
| May 11, 2023 | AMC | -0.71 | -0.63 | +11.3% | 4.47 | +7.2% | +0.4% | +4.3% | +0.4% | +0.2% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Mizuho | Maintains | Outperform → Outperform | — | $2.00 | $2.04 | +2.0% | +5.5% | +9.5% | +16.0% | +18.0% | +12.5% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $2.13 | $2.13 | +0.0% | +0.5% | -3.3% | -6.1% | -0.9% | +2.8% |
| Nov 11 | Stifel | Maintains | Buy → Buy | — | $1.96 | $1.96 | +0.0% | +2.6% | +0.0% | -4.1% | -4.6% | -7.7% |
| Aug 14 | Stifel | Maintains | Buy → Buy | — | $2.21 | $2.18 | -1.4% | -0.5% | +5.4% | +6.3% | +4.1% | +2.3% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $1.96 | $2.00 | +2.0% | +12.8% | +12.2% | +18.9% | +19.9% | +17.3% |
| Jun 10 | Mizuho | Maintains | Outperform → Outperform | — | $1.87 | $1.89 | +1.1% | +6.4% | +7.0% | +2.1% | -0.5% | +1.1% |
| May 15 | William Blair | Downgrade | Outperform → Market Perform | — | $1.87 | $1.78 | -4.8% | -8.0% | -7.0% | -9.1% | -3.7% | -9.1% |
| May 15 | Needham | Maintains | Buy → Buy | — | $1.87 | $1.78 | -4.8% | -8.0% | -7.0% | -9.1% | -3.7% | -9.1% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $1.51 | $1.46 | -3.3% | +4.0% | +1.3% | +4.6% | +12.6% | +13.2% |
| Mar 27 | Stifel | Maintains | Buy → Buy | — | $1.37 | $1.53 | +11.7% | +43.8% | +46.0% | +34.3% | +35.0% | +39.4% |
| Mar 27 | Needham | Maintains | Buy → Buy | — | $1.37 | $1.53 | +11.7% | +43.8% | +46.0% | +34.3% | +35.0% | +39.4% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.37 | $1.53 | +11.7% | +43.8% | +46.0% | +34.3% | +35.0% | +39.4% |
| Nov 21 | Mizuho | Maintains | Outperform → Outperform | — | $2.50 | $2.48 | -0.8% | -2.4% | -2.0% | +3.6% | +4.4% | +19.6% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.19 | $3.23 | +1.3% | +6.3% | -4.4% | -8.8% | -15.4% | -20.7% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $3.27 | $3.29 | +0.6% | -2.4% | +3.7% | -6.7% | -11.0% | -17.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.13 | $5.31 | +3.5% | -2.3% | -1.2% | +1.6% | -0.4% | +4.9% |
| Aug 14 | Needham | Maintains | Buy → Buy | — | $4.97 | $5.45 | +9.7% | +3.2% | +0.8% | +2.0% | +4.8% | +2.8% |
| Aug 14 | Raymond James | Upgrade | Outperform → Strong Buy | — | $4.97 | $5.45 | +9.7% | +3.2% | +0.8% | +2.0% | +4.8% | +2.8% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.84 | $6.73 | -1.6% | -2.9% | +1.0% | +2.9% | -2.2% | -7.2% |
| Jun 28 | Needham | Maintains | Buy → Buy | — | $5.86 | $5.91 | +0.9% | +0.9% | -0.2% | -10.2% | -8.5% | -11.6% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $5.97 | +0.0% | -1.8% | -1.0% | -2.0% | -11.9% | -10.2% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.25 | $6.30 | +0.8% | +5.3% | +4.8% | +10.1% | +9.1% | +4.5% |
| May 13 | Needham | Maintains | Buy → Buy | — | $6.25 | $6.30 | +0.8% | +5.3% | +4.8% | +10.1% | +9.1% | +4.5% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.30 | $6.50 | +3.2% | -0.8% | +4.4% | +4.0% | +9.2% | +8.3% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $8.75 | $8.49 | -3.0% | -7.9% | +0.6% | -0.1% | -0.2% | -11.0% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.49 | $10.81 | +3.1% | -5.9% | +5.7% | +3.1% | +3.1% | -5.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.92 | $10.47 | +17.4% | +17.6% | +10.7% | +24.3% | +21.2% | +21.3% |
| Mar 22 | Mizuho | Maintains | Buy → Buy | — | $12.98 | $10.00 | -23.0% | -31.3% | -19.2% | -24.0% | -14.6% | -16.7% |
| Mar 22 | Raymond James | Downgrade | Strong Buy → Outperform | — | $12.98 | $10.00 | -23.0% | -31.3% | -19.2% | -24.0% | -14.6% | -16.7% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.98 | $10.00 | -23.0% | -31.3% | -19.2% | -24.0% | -14.6% | -16.7% |
| Mar 22 | Needham | Maintains | Buy → Buy | — | $12.98 | $10.00 | -23.0% | -31.3% | -19.2% | -24.0% | -14.6% | -16.7% |
| Mar 5 | Mizuho | Maintains | Buy → Buy | — | $13.09 | $13.18 | +0.7% | +1.0% | +20.0% | +13.7% | +11.8% | +7.0% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.91 | $8.74 | -1.9% | -2.5% | +0.8% | -4.5% | -16.7% | -11.6% |
| Dec 12 | Needham | Maintains | Buy → Buy | — | $2.79 | $2.78 | -0.4% | -0.7% | -0.4% | +5.0% | +14.7% | +11.8% |
| Nov 16 | Mizuho | Maintains | Buy → Buy | — | $2.48 | $2.47 | -0.4% | -5.0% | +5.2% | +5.4% | +2.0% | +4.4% |
| Oct 18 | Needham | Maintains | Buy → Buy | — | $3.14 | $3.17 | +1.0% | -3.2% | -24.8% | -29.9% | -41.6% | -37.6% |
| Oct 18 | Raymond James | Upgrade | Outperform → Strong Buy | — | $3.14 | $3.17 | +1.0% | -3.2% | -24.8% | -29.9% | -41.6% | -37.6% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.14 | $3.17 | +1.0% | -3.2% | -24.8% | -29.9% | -41.6% | -37.6% |
| Oct 17 | Raymond James | Upgrade | Outperform → Strong Buy | — | $1.48 | $1.47 | -0.7% | +112.2% | +105.4% | +59.5% | +48.6% | +24.0% |
| Aug 14 | Mizuho | Maintains | Buy → Buy | — | $1.99 | $2.00 | +0.5% | +0.0% | -0.5% | -1.5% | -5.0% | -7.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.03 | $2.03 | +0.0% | -2.0% | -2.0% | -2.5% | -3.4% | -6.9% |
| Aug 10 | Needham | Maintains | Buy → Buy | — | $2.00 | $2.02 | +1.0% | +1.5% | -0.5% | -0.5% | -1.0% | -2.0% |
| Jun 28 | Raymond James | Maintains | Outperform → Outperform | — | $2.81 | $2.83 | +0.7% | -11.7% | -17.1% | -22.1% | -22.4% | -24.9% |
| Jun 27 | Needham | Maintains | Buy → Buy | — | $4.53 | $4.38 | -3.3% | -38.0% | -45.3% | -48.6% | -51.7% | -51.9% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.53 | $4.38 | -3.3% | -38.0% | -45.3% | -48.6% | -51.7% | -51.9% |
| May 12 | Stifel | Maintains | Buy → Buy | — | $4.47 | $4.79 | +7.2% | +0.4% | +4.3% | +0.4% | +0.2% | +0.7% |
| May 12 | Needham | Maintains | Buy → Buy | — | $4.47 | $4.79 | +7.2% | +0.4% | +4.3% | +0.4% | +0.2% | +0.7% |
| Apr 18 | Needham | Maintains | Buy → Buy | — | $4.61 | $4.65 | +0.9% | +1.1% | +4.8% | +0.4% | +3.5% | -2.6% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $3.75 | $3.70 | -1.3% | +2.4% | +4.0% | -6.1% | -10.1% | -10.1% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.70 | -1.3% | +2.4% | +4.0% | -6.1% | -10.1% | -10.1% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Nektero Therapeutics established an at-the-market offering program allowing flexible equity capital raises, potentially diluting shareholders but providing financial flexibility for development-stage biotech operations.
Mar 26
8-K
Unknown — 8-K Filing
Nkarta's workforce restructuring and clinical team expansion signal focus on autoimmune NK cell development, but cash burn concerns remain critical for investors evaluating runway to key trial milestones.
Mar 25
Data updated apr 26, 2026 3:12pm
· Source: massive.com